SCHEMBL43967

SCHEMBL43967

[N-]=[N+]=CC(=O)OCc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HCAR2 Q8TDS4 1/20 0.59
LMNA P02545 3/20 0.56
ALDH1A1 P00352 5/20 0.52
AKR1B10 O60218 2/20 0.51
AKR1B1 P15121 2/20 0.51
CA12 O43570 1/20 0.51
CA4 P22748 1/20 0.51
CA6 P23280 1/20 0.51
CA5A P35218 1/20 0.51
CA7 P43166 1/20 0.51
CA9 Q16790 1/20 0.51
CA14 Q9ULX7 1/20 0.51
CA5B Q9Y2D0 1/20 0.51
TDP1 Q9NUW8 2/20 0.50
MAPK1 P28482 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
KMT2A Q03164 1/20 0.50
CYP1A2 P05177 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5852336 0.84 MMP1 (0.52) HCAR2LMNATDP1L3MBTL1
SCHEMBL31606878 0.83 HCAR2 (0.61) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL8509226 0.81 CYP17A1 (0.48) LMNAALDH1A1TDP1KMT2ACYP1A2
SCHEMBL7545947 0.80 LMNA (0.57) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL43607 0.80 HCAR2 (0.38) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL337503 0.79 HCAR2 (0.89) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL9395526 0.79 HCAR2 (0.69) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL337504 0.79 HCAR2 (0.89) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL357565 0.79 HCAR2 (0.89) HCAR2LMNAALDH1A1AKR1B10AKR1B1
SCHEMBL42978 0.79 CA12 (0.50) HCAR2LMNAALDH1A1AKR1B10AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250092008-A1 PROCESS FOR MAKING AN EP4 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2025-03-20 US claimed
CN-119219500-A Intermediate of 2, 3-dimethylcyclopropylcarboxylic acid and synthetic method thereof 南通诺泰生物医药技术有限公司 2024-12-31 CN claimed
EP-4384509-A1 PROCESS FOR MAKING AN EP4 ANTAGONIST ONO Pharmaceutical Co., Ltd. (JP) 2024-06-19 EP claimed
WO-2023017813-A1 PROCESS FOR MAKING AN EP4 ANTAGONIST ONO PHARMACEUTICAL CO., LTD. (JP) 2023-02-16 WO claimed
CN-106831764-B A kind of Indoli zine derivatives and preparation method thereof 苏州大学 2018-11-02 CN claimed
CN-106831764-A A kind of Indoli zine derivatives and preparation method thereof 苏州大学 2017-06-13 CN claimed
CN-105884647-A Synthesis method of 3-hydroxyl diazoester intermediate alkyne compound 湖北科技学院 2016-08-24 CN claimed
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2013-06-27 US claimed
EP-2588441-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR Actavis Group Ptc Ehf (IS) 2013-05-08 EP claimed
WO-2012001531-A2 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR ACTAVIS GROUP PTC EHF (IS) 2012-01-05 WO claimed
WO-2011157444-A1 FUNCTIONALIZED MATERIALS BY CATALYZED CARBENE COPOLYMERIZATION STICHTING DUTCH POLYMER INSTITUTE (NL) 2011-12-22 WO claimed
EP-2397509-A1 Functionalized materials by catalyzed carbene copolymerization Stichting Dutch Polymer Institute (NL) 2011-12-21 EP claimed
EP-4688790-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 EP disclosed
EP-4688789-A1 MACROCYCLIC RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-11 EP disclosed
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT 2026-01-29 US disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
US-4548815-A SYNERGISTIC MIXTURE OF AN OXAPENICILLIN AND A PENICILLIN BEECHAM GROUP P.L.C. (GB) 1985-10-22 US disclosed
US-4444685-A Stereospecific synthesis of thienamycin from penicillin MERCK & CO., INC. (US) 1984-04-24 US disclosed
US-4361512-A ANTIBIOTICS MERCK & CO., INC. (US) 1982-11-30 US disclosed
US-4228174-A ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1980-10-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260028353-A1 MACROCYCLIC RAS INHIBITORS KRAS, NRAS, HRAS HCAR2 4158/4885LMNA 2273/4885ALDH1A1 3620/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 HCAR2 3050/4885LMNA 991/4885ALDH1A1 1707/4885
US-20250092008-A1 PROCESS FOR MAKING AN EP4 ANTAGONIST PTGER4, LTB4R2, EPB41 HCAR2 61/4885LMNA 2457/4885ALDH1A1 1405/4885
US-20130165696-A1 NOVEL PROCESSES FOR THE PREPARATION OF PHENYLCYCLOPROPYLAMINE DERIVATIVES AND USE THEREOF FOR PREPARING TICAGRELOR THPO, P2RY4, TBXA2R HCAR2 2713/4885LMNA 3776/4885ALDH1A1 1717/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.